Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
Aurelie Najm AurelieRheumo
3 years 10 months ago
@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D.
Not so surprising considering higher ratio for Fibromyalgia in W
ASDAS not asso w/ gender in AxSPA.
https://t.co/kBxvAi5qZw
Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l
David Liew drdavidliew
3 years 10 months ago
We've never been convinced on adjunct therapy in GCA - yet we're still worried about aortic dilatation.
Beta-blockers we're def not doing - but impressive retrospective data here.
Let's test this properly!
ABST0477 #ACR22 @RheumNow
(also @seminarthrheum https://t.co/onKW2JKIzo) https://t.co/yHTx29NJNX
Dr. Rachel Tate uptoTate
3 years 10 months ago
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Bella Mehta bella_mehta
3 years 10 months ago
Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab - RELIANCE Registry
63% in remission in 2 yrs
serious adverse drug reactions - 1.56 per 100 patient years
@RheumNow #ACR22 abst#0138
Dr. Rachel Tate uptoTate
3 years 10 months ago
@ericdeinmd is moderating a great session, difficult to treat RA at #ACR22 right now! #rheumpix @RheumNow https://t.co/R5yg3eme6v
Dr. John Cush RheumNow
3 years 10 months ago
Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/y7VWk3lOXD
Richard Conway RichardPAConway
3 years 10 months ago
Culerrier @AKronbichler @TerrierBen et al. AAV induced by anti-thyroid drugs. 45 cases. vs AAV - younger (45 vs 68) More skin (54 vs 25%) Less renal (38 vs 73%) Less severe (BVAS 9 vs 13) Less relapse (HR 0.07). Can rechallenge! @rheumnow #ACR22 Abstr#0436 https://t.co/0i7zj615N6 https://t.co/t7fWCOuUsJ
Janet Pope Janetbirdope
3 years 10 months ago
OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9
Richard Conway RichardPAConway
3 years 10 months ago
Dey @DrMiniDey @ElenaNikiUK @docrota @LatikaGupta_ et al. COVID vaccination in IIM+multimorbidity. Adverse events more common, but still infrequent. Both multimorbidity and active IIM increased risk of AEs. @rheumnow #ACR22 Abstr#0177 https://t.co/HA5NaRrPYL https://t.co/TKtagwa0gG
Eric Dein ericdeinmd
3 years 10 months ago
Coming soon on #ACR22:
Stream session 12S119 on @ACRheum and @ACRheumDC advocacy
What is new on the Hill?
What are ACR priorities
How quickly can you send an email supporting rheumatologists (quicker than you think!)
@RheumNow
@AngusWorthing @BlairSolowM @LennMcD @LouisaZiglar https://t.co/sXSBGbCZyM
Richard Conway RichardPAConway
3 years 10 months ago
Froehlich et al. MRI superior to US in GCA. For all GCA sensitivity 73% vs 45%. For supra-aortic GCA sensitivity 73% vs 59%. Both 100% specificity. @rheumnow #ACR22 Abstr#0493 https://t.co/vf2r0h5zUd https://t.co/mlSCcpy2uK
Robert B Chao, MD doctorRBC
3 years 10 months ago
Very complex conversation on why opioids are used...
Opioid use in patients with PsA and AS led to higher healthcare utilization and higher costs.
Opioid users - more co-morbidities, smokers, worse disease activity
Opioid users spent more on drug costs
Abs#0402 @RheumNow #ACR22 https://t.co/dbUPg5LGLy
Richard Conway RichardPAConway
3 years 10 months ago
Rathmann et al. Incidence/Prevalence AAV in Sweden over time. Incidence stable. Prevalence increasing and higher in men. Incidence increases with age and commonest 70-84 years @rheumnow #ACR22 Abstr#0451 https://t.co/yCMOC7dAvq https://t.co/y0tqkaV8zX
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR22 Abstr#2081 What is the nature of breakthrough #COVID infection in #lupus patients in Omicron era? A cohort study in New York showed those receiving booster vac were less likely to develop infection vs receiving 2 vaccine doses. Only 2 hospitalised, no deaths @RheumNow https://t.co/6UaTMN5Dev
Richard Conway RichardPAConway
3 years 10 months ago
Rooney et al. Seasonality of GCA in UK and Ireland - DCVAS/TABUL/local hospital combined dataset. 2 peaks - spring/early summer every year, and a second peak most years in autumn or winter. @rheumnow #ACR22 Abstr#0495 https://t.co/Trz8ou9xGh https://t.co/jcS3Z30nz8
